The present study found no significant differences in the time to achieve target, daily total and basal insulin doses, daily per body weight unit total and basal insulin doses between Groups B and C (P > 0.05) suggesting that the efficacy of detemir and glargine may be comparable in subjects with T2DM when combined with aspart in a basal-bolus regimen. This evidence concerns the gene INS and type 2 diabetes mellitus.